Funds similar to Bajaj Finserv Healthcare Fund Direct-Growth in the Equity: Sectoral-Pharma category include Nippon India Pharma Fund Direct-Growth, ICICI Prudential Healthcare Fund Direct-Growth, and SBI Healthcare Opportunities Fund Direct Plan-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.

The category rank of Bajaj Finserv Healthcare Fund Direct-Growth is shown in the Trailing Returns section above.

Bajaj Finserv Healthcare Fund Direct-Growth has an expense ratio of 0.90%. The peers Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99% and ICICI Prudential Healthcare Fund Direct-Growth has 1.31%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.

Bajaj Finserv Healthcare Fund Direct-Growth has an AUM of ₹376.77 crore. The peers Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,279.11 crore and ICICI Prudential Healthcare Fund Direct-Growth has ₹6,802.61 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.

The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is UTI Healthcare Fund Direct-Growth with a CAGR of 24.47% as of 6 Sep 2026. Bajaj Finserv Healthcare Fund Direct-Growth has delivered - CAGR over the same period. You can view and compare the full category ranking on sharpely.

The Sharpe ratio of Bajaj Finserv Healthcare Fund Direct-Growth is shown in the Alpha, Beta & Sharpe section on the Performance tab.